Published Papers & Misc - YOKOYAMA Minato

Division display  21 - 40 of about 102 /  All the affair displays >>
  1. Toshiki Kijima, Hiroshi Fukushima, Shota Kusuhara, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Noboru Numao, Yasuyuki Sakai, Kazutaka Saito, Nobuaki Matsubara, Takeshi Yuasa, Hitoshi Masuda, Junji Yonese, Yukio Kageyama, Yasuhisa Fujii. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clin Genitourin Cancer. 2021.06; 19 (3): 208-216.e1. ( PubMed, DOI )

  2. Yosuke Yasuda, Kazutaka Saito, Hajime Tanaka, Sho Uehara, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Kazunori Kihara, Yasuhisa Fujii. Outcomes of gasless laparoendoscopic single-port partial nephrectomy in 356 consecutive patients: Feasibility of a clampless and sutureless technique. Int J Urol. 2021.03; 28 (3): 302-307. ( PubMed, DOI )

  3. Toshiki Kijima, Hina Yamamoto, Kazutaka Saito, Shota Kusuhara, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Noboru Numao, Yasuyuki Sakai, Nobuaki Matsubara, Takeshi Yuasa, Hitoshi Masuda, Junji Yonese, Yukio Kageyama, Yasuhisa Fujii. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021.03; 70 (3): 657-665. ( PubMed, DOI )

  4. Shohei Fukuda, Kazutaka Saito, Yosuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Yukio Kageyama, Yasuhisa Fujii. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 2021.02; 9 (2): ( PubMed, DOI )

  5. Soichiro Yoshida, Taro Takahara, Minato Yokoyama, Yoh Matsuoka, Ryoichi Yoshimura, Yasuhisa Fujii. Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer? Int J Urol. 2021.02; 28 (2): 241-242. ( PubMed, DOI )

  6. Yoh Matsuoka, Sho Uehara, Soichiro Yoshida, Hajime Tanaka, Minato Yokoyama, Yasuhisa Fujii. Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems. Int J Urol. 2021.01; 28 (1): 127-129. ( PubMed, DOI )

  7. Hiroshi Fukushima, Toshiki Kijima, Shohei Fukuda, Shingo Moriyama, Sho Uehara, Yosuke Yasuda, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Kazutaka Saito, Nobuaki Matsubara, Noboru Numao, Yasuyuki Sakai, Takeshi Yuasa, Hitoshi Masuda, Junji Yonese, Yukio Kageyama, Yasuhisa Fujii. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Med. 2020.11; 9 (22): 8355-8363. ( PubMed, DOI )

  8. Minato Yokoyama, Hitoshi Masuda, Masaya Ito, Yuma Waseda, Shingo Moriyama, Masahiro Toide, Yusuke Uchida, Sho Uehara, Toshiki Kijima, Soichiro Yoshida, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii. Longitudinal changes in patient-reported outcomes after artificial urinary sphincter implantation. Low Urin Tract Symptoms. 2020.09; 12 (3): 240-244. ( PubMed, DOI )

  9. Ishii A, Yokoyama M, Tsuji H, Fujii Y, Tamaoka A. Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis eNeurologicalSci. 2020.04;

  10. Waseda Y, Kobayashi S, Kanda E, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model Clin Genitourin Cancer. 2020.04;

  11. Nakamura Y, Yokoyama M, Yoshida S, Tanaka H, Kijima T, Ishioka J, Matsuoka Y, Saito K, Minami I, Yoshimoto T, Naito S, Ogawa Y, Yamada T, Uchida S, Fujii Y. Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome Int J Urol. 2020 Mar 11. doi: 10.1111/iju.14205. 2020.03;

  12. Kaneko K, Yoshida S, Yamamoto K, Arita Y, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. . Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted magnetic resonance imaging. Int J Urol. 2020 Jul;27(7):599-604. doi: 10.1111/iju.14251.. 2020;

  13. Tanaka H, Fukushima H, Kijima T, Nakamura Y, Yajima S, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer Int J Urol. 2020; 27: 236-243. *Equal contribution. 2020;

  14. Matsuoka Y, Uehara S, Yoshida S, Tanaka H, Tanaka H, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y. Value of extra-target prostate biopsy for the detection of magnetic resonance imaging-missed adverse pathology according to the Prostate Imaging Reporting and Data System scores Spatial analysis using magnetic resonance-ultrasound fusion images. Int J Urol. 2020; 27: 760-766. 2020;

  15. Fukushima H, Moriyama S, Waseda Y, Fukuda S, Uehara S, Tanaka H, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer Eur Urol Focus. 2020;

  16. Fukushima H, Inoue M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Incidence and risk factors of hypertension following partial nephrectomy in patients with renal tumors: a cross-sectional study of postoperative home blood pressure and antihypertensive medications Clin Genitourin Cancer. 2020;

  17. Fukushima H, Fukuda S, Moriyama S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report Anticancer Drugs. 2020; 31: 866-871. doi: 10.1097/CAD.0000000000000982.. 2020;

  18. Ishii A, Yokoyama M, Tsuji H, Fujii Y, Tamaoka A. Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis eNeurologicalSci. 2020;

  19. Kobayashi M, Yokoyama M, Inoue M, Fujii Y. Undifferentiated prostate cancer treated with docetaxel IJU Case Reports. 2020;

  20. SoichiroYoshida1TaroTakahara23ChikakoIshii3YukiArita34YumaWaseda1ToshikiKijima1MinatoYokoyama1JunichiroIshioka1YohMatsuoka1KazutakaSaito1YasuhisaFujii. METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer 2019.12;

To the head of this page.▲